Table 2. Summary of role and potential clinical application of SNHG in hematopoietic malignancy

| SNHG  | Expression | Disease Subtype             | Potential application | clinical application | Reference |
|-------|------------|-----------------------------|-----------------------|----------------------|-----------|
| SNHG18| Overexpression| t(4;14)-positive MM        | N.A                   |                      | 49        |
| SNHG12| Overexpression| DLBCL                      | N.A                   |                      | 50        |
| SNHG14| Overexpression| DLBCL                      | N.A                   |                      | 52        |
| SNHG16| Overexpression| DLBCL                      | N.A                   |                      | 53        |
| SNHG16| Overexpression| AML                        | N.A                   |                      | 62        |
| SNHG5 | Overexpression| AML                        | N.A                   |                      | 63        |
| SNHG1 | Overexpression| AML                        | Prognostic marker     |                      | 64,65     |
| SNHG4 | Downregulation| AML                        | N.A                   |                      | 66        |
| SNHG5 | Overexpression| CML                        | N.A                   |                      | 68        |
| SNHG5 | Downregulation| T-ALL                      | Therapeutic target    |                      | 74        |
| SNHG16| Overexpression| ALL                        | N.A                   |                      | 75        |

N.A., not applied